Apellis Pharmaceuticals Inc APLS:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 02/26/21 EST
48.17UNCH (UNCH)
Volume
27,326
Close
48.17quote price arrow up+3.12 (+6.93%)
Volume
767,251
52 week range
16.85 - 58.47

...

Loading . . .

KEY STATS

  • Open45.86
  • Day High49.12
  • Day Low45.34
  • Prev Close45.05
  • 52 Week High58.47
  • 52 Week High Date01/07/21
  • 52 Week Low16.85
  • 52 Week Low Date03/18/20
  • Market Cap3.836B
  • Shares Out79.64M
  • 10 Day Average Volume0.47M
  • Dividend-
  • Dividend Yield-
  • Beta
  • 1 Year % Change43.36

RATIOS/PROFITABILITY

  • EPS (TTM)-4.62
  • P/E (TTM)-10.42
  • Fwd P/E (NTM)-8.75
  • EBITDA (MRQ)-449.33M
  • ROE (MRQ)-437.13%
  • Revenue (MRQ)650,000.00
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-83,027.31%
  • Debt To Equity (MRQ)334.25%

EVENTS

  • Earnings Date04/27/2021
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest Apellis Pharmaceuticals Inc News

There is no recent news for this security.

QUOTE FINDER

Profile

MORE
Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases. The Company's lead compounds are designed to inhibit complement component 3 (C3), the central protein in the complement cascade. The Company’s lead product candidate is APL-2. APL-2 is Phase III clinical trials developed for the treatment of geographic atrophy (GA) and intermediate...
Gerald Chan Ph.D.
Chairman
Cedric Francois M.D. Ph.D.
President
Timothy Sullivan
Chief Financial Officer
David Watson
Vice President
Nicole Perry
Vice President - Finance
Address
100 5th Avenue
Waltham, MA
02451
United States